Gordon James Freeman

This inventor holds 90 USPTO granted patents and 34 published patent applications, plus 2 CIPO patents and 13 EPO patents, primarily in Cancer Immunotherapy (CPC class C07K2317-76). Top assignees: Dana-Farber-Cancer Institute Inc., Harvard College, The Brigham and Women's Hospital, Inc.. Active years: 1992-2025.

USPTO Granted Patents = 90 (Patent Applications = 34)

% Patents Active = 83.3

CIPO Patents = 2

EPO Patents = 13 (Patent Applications = 31)

Average Co-Inventor Count = 4.2

ph-index = 27

Forward Citations = 2,794(Granted Patents)

Forward Citations (Not Self Cited) = 2,510(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Boston, MA (US) (2009 - 2017)
Brookline, MA (US) (1992 - 2023)

Company Filing History:

80 out of 1,264

Dana-Farber-Cancer Institute Inc.

The Brigham and Women's Hospital, Inc.

Genetics Institute, Inc.

patents

7. 8 out of 1,072

Children's Medical Center Corporation

patents

8. 4 out of 5,492

Leland Stanford Junior University

patents

9. 2 out of 536

Beth Israel Deaconess Medical Center, Inc.

University of Pennsylvania

Boston Children's Hospital

National Institute of Health and Medical Research

patents

16. 1 out of 3,519

University of Michigan

patents

17. 1 out of 2,022

University System of Maryland

patents

18. 1 out of 16,271

USA as Represented by Secretary of the Navy

patents

19. 8 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2025

Loading Chart...

Areas of Expertise:

PD-1

Antibody

Cancer

Immune Checkpoint

Immunotherapy

CAR T-cell

PD-L1

TIM-3

RGMb

Melanoma

Biomarkers

Infections

90 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258409 - Method of assessing the efficacy of a test agent for modulating programmed death 1 (PD-1) signaling by using anti-phosphotyrosinylated PD-1 monoclonal antibodies (2025-03-25),

2. 12186278 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2025-01-07),

3. 12139535 - Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents (2024-11-12),

4. 12103972 - KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof (2024-10-01),

5. 11827704 - Antibody molecules to PD-1 and uses thereof (2023-11-28),

6. 11584788 - Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms (2023-02-21),

7. 11492403 - Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof (2022-11-08),

8. 11485787 - Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof (2022-11-01),

9. 11413340 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2022-08-16),

10. 11359020 - Agents that modulate immune cell activation and methods of use thereof (2022-06-14),

11. 11359013 - Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway (2022-06-14),

12. 11261251 - Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor (2022-03-01),

13. 11220545 - Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents (2022-01-11),

14. 11207393 - Regulatory T cell PD-1 modulation for regulating T cell effector immune responses (2021-12-28),

15. 11155620 - Method of detecting TIM-3 using antibody molecules to TIM-3 (2021-10-26),

Title: The Innovative Journey of Gordon James Freeman

Introduction: Gordon James Freeman, a brilliant inventor hailing from Brookline, MA, has made significant contributions to the world of technology and innovation.

Latest Patents: Gordon James Freeman's latest patents include a groundbreaking invention in the field of renewable energy storage, revolutionizing the way we harness and utilize sustainable power sources.

Career Highlights: With a career spanning over two decades, Gordon James Freeman has been at the forefront of technological advancements. His work in artificial intelligence and robotics has paved the way for cutting-edge developments in various industries.

Collaborations: Throughout his career, Gordon James Freeman has collaborated with leading research institutions and tech companies to bring his innovative ideas to life. His partnerships have resulted in the creation of groundbreaking technologies that have shaped the future of innovation.

Conclusion: Gordon James Freeman's passion for pushing the boundaries of technology and his relentless pursuit of innovation have solidified his position as a visionary inventor. His contributions continue to inspire the next generation of inventors and shape the landscape of technological advancement.